Sugammadex Dosing Examined in Obese Patients to Reverse Neuromusclar Blockade

This article originally appeared here.
Dose of Sugammadex to reverse neuromuscular blockade in obese patients
Dose of Sugammadex to reverse neuromuscular blockade in obese patients

(HealthDay News) — Sugammadex at a dose of 4 mg/kg−1 of ideal body weight allows for shorter reversal of deep neuromuscular blockade in morbidly obese patients, according to a study published in the March issue of Anaesthesia.

Thibault Loupec, M.D., from the University of Poitiers in France, and colleagues conducted a single-center randomized trial in 50 morbidly obese patients. Neuromuscular blockade was monitored using acceleromyography at the adductor pollicis. Patients were randomized to sugammadex 4 mg/kg−1 (high-dose group), 2 mg/kg−1 (middle-dose group), and 1 mg/kg−1 (low-dose group) of ideal body weight at the end of surgery with deep rocuronium-induced neuromuscular blockade.

The researchers found that the mean recovery time from deep neuromuscular blockade was significantly shorter in the high-dose group versus the middle- or low-dose group after administration of the first dose of sugammadex (255 versus 429 and 581 seconds, respectively; P < 0.001). For the high-, middle-, and low-dose groups, success rates were 93, 77, and 22 percent, respectively, from neuromuscular blockade reversal defined by a train-of-four ≥0.9 within 10 minutes after sugammadex administration (P < 0.05 compared with the lose-dose group).

"In morbidly obese patients, 4 mg/kg−1 of ideal body weight of sugammadex allows suitable reversal of deep rocuronium-induced neuromuscular blockade," the authors write. "Monitoring remains essential to detect residual curarisation or recurarisation."

One author disclosed financial ties to Merck Sharp & Dohme.

Full Text (subscription or payment may be required)